And the winner is?
This article was originally published in The Tan Sheet
Cogene Biotech Ventures CEO Thomas Caskey, MD, and Stanford University School of Medicine cardiology professor Paul Yock, MD, are now being considered as FDA Commissioner candidates by Bush Administration. Strong ties to academia (Caskey taught at Baylor College of Medicine for 25 years) probably is major reason for recent consideration; Senate Health Committee Chairman Edward Kennedy (D-Mass.) discouraged Administration from nominating candidates with ties to industry in a July 13 letter (1"The Tan Sheet" July 23, p. 17)
You may also be interested in...
The key attributes for the next FDA commissioner - from Sen. Edward Kennedy's point of view - appear to lend support to the candidacy of Harvard Medical School dermatology lecturer Lynn Drake, MD.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning